Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 1884 2023-04-25 20:15:50 |
2 layout & references Meta information modification 1884 2023-04-26 10:52:57 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Huang, J.; Sigon, G.; Mullish, B.H.; Wang, D.; Sharma, R.; Manousou, P.; Forlano, R. Lipidomics in Non-Alcoholic Fatty Liver Disease. Encyclopedia. Available online: https://encyclopedia.pub/entry/43481 (accessed on 22 April 2024).
Huang J, Sigon G, Mullish BH, Wang D, Sharma R, Manousou P, et al. Lipidomics in Non-Alcoholic Fatty Liver Disease. Encyclopedia. Available at: https://encyclopedia.pub/entry/43481. Accessed April 22, 2024.
Huang, Jian, Giordano Sigon, Benjamin H. Mullish, Dan Wang, Rohini Sharma, Pinelopi Manousou, Roberta Forlano. "Lipidomics in Non-Alcoholic Fatty Liver Disease" Encyclopedia, https://encyclopedia.pub/entry/43481 (accessed April 22, 2024).
Huang, J., Sigon, G., Mullish, B.H., Wang, D., Sharma, R., Manousou, P., & Forlano, R. (2023, April 25). Lipidomics in Non-Alcoholic Fatty Liver Disease. In Encyclopedia. https://encyclopedia.pub/entry/43481
Huang, Jian, et al. "Lipidomics in Non-Alcoholic Fatty Liver Disease." Encyclopedia. Web. 25 April, 2023.
Lipidomics in Non-Alcoholic Fatty Liver Disease
Edit

The prevalence of non-alcoholic fatty liver disease (NAFLD) and associated complications, such as hepatocellular carcinoma (HCC), is growing worldwide, due to the epidemics of metabolic risk factors, such as obesity and type II diabetes. Among other factors, an aberrant lipid metabolism represents a crucial step in the pathogenesis of NAFLD and the development of HCC in this population.

lipidomics NAFLD NASH fibrosis

1. Lipid Metabolism and Lipotoxicity in the Pathogenesis of NAFLD

The accumulation of hepatic triglycerides represents the crucial step for the development of the disease. Overall, a reduced fatty acid β-oxidation and very-low-density lipoprotein (VLDL) export are associated with the massive accumulation of fatty acids and triglycerides in the liver [1]. Subsequently, the mismatch between β-oxidation and the oxidative phosphorylation leads to oxidative stress, which, in turn, contributes to lipotoxicity, cellular damage, and fibrosis progression [2][3]. Moreover, the resulting production of reactive oxygen species (ROS) induces mitochondrial dysfunction, which, in turn, exacerbates ROS production and, ultimately, lipotoxicity [4][5]. An aberrant mitochondrial lipid metabolism contributes to the dysfunction of the electron transport chain (ETC), and it also induces the expression of Sirtuin (SIRT) 3 and the damage of mitochondrial DNA [4].
Lipotoxicity represents a crucial step in the pathogenesis of NAFLD and the progression to NASH, as it may lead to the accumulation of toxic lipids in the hepatocyte. It is also the hallmark of the diagnosis of NASH [6]. Lipotoxicity translates into organellar dysfunction, abnormal activation of signaling intracellular signaling pathways, chronic inflammation, and, ultimately, apoptosis [7][8]. The underlying mechanism involves several cellular components, such as endoplasmic reticulum (ER) stress, lysosomal permeabilization, and mitochondrial dysfunction. Specifically, histology from patients with NASH showed defective electron transport chain (ETC) function together with specific morphological alterations, such as enlarged mitochondria, rounded cristae, and alterations of the mitochondrial DNA [9]. An incomplete β-oxidation of fatty acids, such as palmitic acid, has been shown to impair mitochondrial function, as it may disrupt the ETC directly via the activation of phosphatases [6][10]. Such changes may lead to the accumulation of ROS and other toxic metabolites, such as superoxide, palmitic acid, and ceramides [11][12][13]. An increased amount of superoxide may, in turn, generate further oxidative damage and sustain both lipotoxicity and cellular membrane damage [6]. In addition to mitochondrial dysfunction, lipotoxicity may cause ER stress. For instance, a previous lipidomic study carried out on liver tissue reported that the high level of diglycerides, ceramides, phospholipids, and saturated fatty acid can directly induce the ER stress by the activation of the Unfolded protein Response (UPR) and the expression of pro-apoptotic molecules, such as B-cell lymphoma 2 (BLC2) [11][13]. Furthermore, apoptosis may be induced directly by saturated free fatty acids via both intrinsic and extrinsic pathways. The ER and the oxidative stress caused by accumulated FFAs stimulate the activation of C/EBP Homologous Protein (CHOP) and the cJUN NH2-terminal kinase (JNK) pathway. The activation of CHOP and JNK is then followed by the upregulation of more pro-apoptotic factors and the release of cytochrome C and caspase 9 [6]. Lipotoxicity has also been associated with greater intra-hepatic inflammation. For instance, toxic lipid metabolites, such as palmitate, can induce the production of pro-inflammatory factors by activated macrophages via TNF-related apoptotic factors [14]. Furthermore, it has been demonstrated that hepatocytes, under the stimulation of saturated fatty acid, may release pro-inflammatory cytokines (i.e., CXC-chemokine ligand 10 (CXCL10)), which further sustain inflammatory response and cellular damage. Finally, in patients with NASH, lipotoxicity has been associated with impaired autophagy in the form of defective phagosome formation and lysosomal acidification [15]. Specifically, a mixture of palmitic and oleic acid has been shown to inhibit autophagic flux and reduce lipophagy, contributing to the vicious circle of lipotoxicity-induced damage [16].
After being exposed to toxic lipids, injured hepatocytes release a large group of extracellular vesicles, such as exosomes, microparticles, and apoptotic bodies. These byproducts may not only perpetuate inflammation but may also elicit fibrosis by activating non-parenchymal cells [17]. Moreover, apoptotic bodies will be included by stellate cells and then active them into HSC activation, with the production of α–smooth muscle actin and collagen [18]. Some recent evidence also suggests that toxic fatty acids may be able to stimulate Kupffer cells and HSCs directly. For instance, palmitic acids induce toll-like receptor (TLR) 2 and TLR4 in macrophages and activate a pro-inflammatory response in KCs [19]. Palmitate can also elicit actin production from activated HSCs [19].
In terms of specific lipid species, phosphocholine is one of the main components of cell membranes and of lipid droplets and plays a crucial role in maintaining physiological cellular activities. Imbalances in the phosphocholine expression may result into hepatocyte dysfunction and have been associated with NAFLD development and progression [4][5][20][21]. Interestingly, there has been evidence suggesting that even changes in the structure of lipids may translate into different biological effects. For instance, an odd-chain phosphatidylcholine was reported to have a negative correlation with the progression of NAFLD [22]. In addition to the structure of lipids, the level of diversity lipids shows a close correlation with the progression from the normal liver to NAFLD. Specifically, a lower level of ceramides, a lipid species that modulates cell proliferation, and a lower level of polyunsaturated triglycerides were both previously associated with an impaired metabolism of the hepatocytes [23][24][25]. Conversely, supplementation with ceramides and polyunsaturated triglycerides was shown to have a hepato-protective effect via promoting the apoptosis of aberrant hepatocytes [26]. There has also been recent evidence suggesting that the regulation of the expression of lipids may influence the development and progression of NAFLD. For instance, PPARα knock-out mice, when starved, rapidly develop fatty liver disease, as the inhibition of CPT1a accumulates fatty acids in hepatocytes [27][28]. Moreover, SREBPs have been identified as possible oncogenes in the pathogenesis of hepatocarcinoma [29][30].
Finally, bile acids (BAs) have also been involved in the pathogenesis and progression of NAFLD. BAs are synthesized from cholesterol in hepatic tissue; thus BAs are characterized by amphipathic molecules. This unique character leads BAs to solubilize the lipid bilayer [31], which can result in the disruption of cellular structure. Therefore, the high level of intracellular BAs can increase the high risk of apoptosis and promote the infiltration of inflammatory factors [32]. Furthermore, BAs can directly interact with the gut microbiota in the intestinal compartment. Growing evidence suggests that BAs have a significant influence on the progression of NAFLD and NASH via affecting the gut microbiota to regulate the hepatic lipids [32][33]. However, the precise mechanism of the apoptosis signaling pathway induced by the BAs’ metabolism in cellular activities is unclear.
To conclude, there is evidence suggesting that both composition and regulation of hepatic lipids may impact the development and progression of NAFLD.

2. Translational Lipidomics for Diagnosing NAFLD

Overall, hundreds of lipids species in serum and hepatic tissue, triglycerides, diglycerides, sphingolipids and cholesteryl esters have shown a significant difference of species in patients with NAFLD compared to healthy controls [22][34][35][36][37][38][39][40]. A previous study using liquid chromatography mass spectrometry (LC-MS) suggested that serum levels of phosphatidylethanolamines (PE), phosphocholine (PC), and sphingomyelin (SM) were able to distinguish the patients with NAFLD from healthy controls [35]. Peng et al. identified that saturated triglycerides were increased whereas polyunsaturated triglycerides were reduced in NAFLD compared to healthy controls [22]. Consistent with Peng’s results, Gorden et al. also found that up to 15 triglycerides and 7 cholesteryl esters were up-regulated in the hepatic tissue of NAFLD patients [34]. Across different studies, nine lipids were consistently increased in patients with NAFLD: phosphocholine (PI)(40:5), triglyceride (TG) (52:4), diacylglycerol (DG) (34:2), and diacylglycerol(DG)(36:2) [22][34][35][36][39]. Along with quantitative changes of circulatory lipids, there seems to be a difference in the distribution of lipids in the liver of NAFLD patients, too. Three-dimensional studies have shown that low-density lipoprotein and very low-density lipoproteins are more abundant in the steatotic regions, whereas phosphatidylinositol and arachidonic acid prevail in the fat-sparing areas of the same livers [41].
From a clinical perspective, the lipid profile appears to be different in patients with NAFLD depending on the presence of different risk factors and genetic predisposition. Of note, in a study using LC-MS, diacylglycerol, triglyceride, and sphingomyelin were found to be significantly increased in the sera of obese patients with NAFLD compared to lean NAFLD, suggesting a direct influence of visceral adiposity [42]. Moreover, in a study using direct flow injection electrospray ionization tandem mass spectrometry (ESI–MS/MS), saturated ceramide-enriched liver lipidome was observed in those with NASH in the context of metabolic syndrome and insulin resistance, but not in those with “genetic-driven”, PNPLA3-associated NASH, i.e., those carrying I148M variant of the gene [43]. Furthermore, another recent study demonstrated that carriers of the HSD17B13 variant have increased phospholipids in their liver but have minimal fibrosis [44]. Interestingly, in this group, the presence of phospholipids was independent of hepatic insulin sensitivity. Ethnicity may also influence the lipid profile in these patients, as Hispanics were found to have higher FFA and lysophospholipids than Caucasians, indicating ethnic-related lipidomic signatures [45].
Overall, these results suggest that a distinct lipid profile reflects different combinations of metabolic risk factors and the clinical phenotype of the patient, suggesting the role of lipidomics in precision medicine.

3. Translational Lipidomics for Staging NAFLD

Despite being the gold standard for the diagnosis and staging of NAFLD, liver biopsies carry several risks, such as cost, bleeding risk, and pain for the patient [35][46]. For this reason, the research on biomarkers for NAFLD has been flourishing over the past few years. Interestingly, it has been demonstrated that alterations in the liver tissue lipidome reflect the lipid profile measurement in the plasma, opening the field for the use of a lipid profile as a biomarker for the histological features of NASH [47]. A combination of circulating lipids may improve the diagnosis and risk-stratification in patients with NAFLD and may identify those with NASH accurately [35][36]. In a group of NAFLD patients, a score combining serum lipids, assessed by nanoparticle-tracking techniques, and genetic variants was able to predict fat fraction, as measured by MRI-PDFF [48]. Moreover, in a cohort of patients with biopsy-proven NASH, phosphatidylcholine levels, assessed by LC-MS, were strongly associated with severity of ballooning [49]. In a similar study, phosphocholine (14:0/18:2) and phosphatidic acid (18:2/24:4) were positively correlated with NAS score, whereas phosphocholine (18:0/0:0) was correlated positively with the fibrosis stage [50]. Lipidomics may also be a useful tool to predict disease progression. Using the same lipidomic technique, researchers previously demonstrated that a score combining metabolic profile and lipoproteins was able to identify fast fibrosis progressors and performed better than noninvasive markers [51].
From a clinician’s perspective, cardiovascular events are the main cause of morbidity and mortality in patients with NAFLD [52]. Nevertheless, identifying those at higher risk for cardiovascular events in this population remains a challenge [53]. Interestingly, ectopic fat deposits, such as myocardial and epicardial fat, show a specific lipid composition, which is different from the hepatic one [54]. Moreover, a higher abundance of diacylglycerol and ceramide (Cer) in the ectopic fat deposits, measured by LC-MS, seems to be associated with an overall stronger lipotoxicity effect [55]. Overall, these results suggest that lipidomics may be employed to identify those at risk of MACE in this population.
Finally, lipidomic approaches may also provide more insight into metabolic changes with different treatments in patients with NAFLD. A 6-month treatment with polyunsaturated fatty acids was able to change the lipid profile of patients with NASH, resulting in an underlying lower lipogenesis, endoplasmic reticulum stress, and mitochondrial dysfunction [56]. Similarly, in patients who underwent weight loss, there was a significant decrease in circulating lysophospholipids [57]. More studies are required to evaluate how the changes in lipidomic profile may be translated into clinical events.

References

  1. Mato, J.M.; Alonso, C.; Noureddin, M.; Lu, S.C. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J. Gastroenterol. 2019, 25, 3009.
  2. Ipsen, D.H.; Lykkesfeldt, J.; Tveden-Nyborg, P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell. Mol. Life Sci. 2018, 75, 3313–3327.
  3. Musso, G.; Gambino, R.; Cassader, M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res. 2013, 52, 175–191.
  4. Kim, G.-A.; Lee, H.C.; Choe, J.; Kim, M.-J.; Lee, M.J.; Chang, H.-S.; Bae, I.Y.; Kim, H.-K.; An, J.; Shim, J.H. Association between non-alcoholic fatty liver disease and cancer incidence rate. J. Hepatol. 2018, 68, 140–146.
  5. Sunami, Y. NASH, fibrosis and hepatocellular carcinoma: Lipid synthesis and glutamine/acetate signaling. Int. J. Mol. Sci. 2020, 21, 6799.
  6. Rada, P.; González-Rodríguez, Á.; García-Monzón, C.; Valverde, Á.M. Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver? Cell Death Dis. 2020, 11, 802.
  7. Schweiger, M.; Romauch, M.; Schreiber, R.; Grabner, G.F.; Hütter, S.; Kotzbeck, P.; Benedikt, P.; Eichmann, T.O.; Yamada, S.; Knittelfelder, O.; et al. Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice. Nat. Commun. 2017, 8, 14859.
  8. Samuel, V.T.; Shulman, G.I. Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell 2012, 148, 852–871.
  9. Pirola, C.J.; Gianotti, T.F.; Burgueño, A.L.; Rey-Funes, M.; Loidl, C.F.; Mallardi, P.; Martino, J.S.; Castaño, G.O.; Sookoian, S. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2012, 62, 1356–1363.
  10. Egnatchik, R.A.; Leamy, A.K.; Noguchi, Y.; Shiota, M.; Young, J.D. Palmitate-induced Activation of Mitochondrial Metabolism Promotes Oxidative Stress and Apoptosis in H4IIEC3 Rat Hepatocytes. Metabolism 2014, 63, 283–295.
  11. Svegliati-Baroni, G.; Pierantonelli, I.; Torquato, P.; Marinelli, R.; Ferreri, C.; Chatgilialoglu, C.; Bartolini, D.; Galli, F. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free Radic. Biol. Med. 2019, 144, 293–309.
  12. Patterson, R.E.; Kalavalapalli, S.; Williams, C.M.; Nautiyal, M.; Mathew, J.T.; Martinez, J.; Reinhard, M.K.; McDougall, D.J.; Rocca, J.R.; Yost, R.A. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. Am. J. Physiol.-Endocrinol. Metab. 2016, 310, E484–E494.
  13. Béland-Bonenfant, S.; Rouland, A.; Petit, J.-M.; Vergès, B. Concise review of lipidomics in nonalcoholic fatty liver disease. Diabetes Metab. 2023, 49, 101432.
  14. Hirsova, P.; Ibrahim, S.H.; Krishnan, A.; Verma, V.K.; Bronk, S.F.; Werneburg, N.W.; Charlton, M.R.; Shah, V.H.; Malhi, H.; Gores, G.J. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology 2016, 150, 956–967.
  15. Wang, X.; Zhang, X.; Chu, E.S.H.; Chen, X.; Kang, W.; Wu, F.; To, K.F.; Wong, V.W.S.; Chan, H.L.Y.; Chan, M.T.V.; et al. Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. FASEB J. 2018, 32, 37–51.
  16. Zhang, T.; Liu, J.; Shen, S.; Tong, Q.; Ma, X.; Lin, L. SIRT3 promotes lipophagy and chaperon-mediated autophagy to protect hepatocytes against lipotoxicity. Cell Death Differ. 2019, 27, 329–344.
  17. Marra, F.; Svegliati-Baroni, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J. Hepatol. 2018, 68, 280–295.
  18. Kwon, H.; Song, K.; Han, C.; Chen, W.; Wang, Y.; Dash, S.; Lim, K.; Wu, T. Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease. Hepatol. 2015, 63, 1155–1169.
  19. Shi, H.; Kokoeva, M.V.; Inouye, K.; Tzameli, I.; Yin, H.; Flier, J.S. TLR4 links innate immunity and fatty acid–induced insulin resistance. J. Clin. Investig. 2006, 116, 3015–3025.
  20. Roehlen, N.; Crouchet, E.; Baumert, T.F. Liver fibrosis: Mechanistic concepts and therapeutic perspectives. Cells 2020, 9, 875.
  21. Bedossa, P.; Patel, K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. Gastroenterology 2016, 150, 1811–1822.
  22. Peng, K.-Y.; Watt, M.J.; Rensen, S.; Greve, J.W.; Huynh, K.; Jayawardana, K.S.; Meikle, P.J.; Meex, R.C. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression. J. Lipid Res. 2018, 59, 1977–1986.
  23. Li, Z.; Guan, M.; Lin, Y.; Cui, X.; Zhang, Y.; Zhao, Z.; Zhu, J. Aberrant lipid metabolism in hepatocellular carcinoma revealed by liver lipidomics. Int. J. Mol. Sci. 2017, 18, 2550.
  24. Lu, Y.; Chen, J.; Huang, C.; Li, N.; Zou, L.; Chia, S.E.; Chen, S.; Yu, K.; Ling, Q.; Cheng, Q. Comparison of hepatic and serum lipid signatures in hepatocellular carcinoma patients leads to the discovery of diagnostic and prognostic biomarkers. Oncotarget 2018, 9, 5032.
  25. Krautbauer, S.; Meier, E.M.; Rein-Fischboeck, L.; Pohl, R.; Weiss, T.S.; Sigruener, A.; Aslanidis, C.; Liebisch, G.; Buechler, C. Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma. Mol. Cell Biol. Lipids 2016, 1861, 1767–1774.
  26. Sakakima, Y.; Hayakawa, A.; Nagasaka, T.; Nakao, A. Prevention of hepatocarcinogenesis with phosphatidylcholine and menaquinone-4: In vitro and in vivo experiments. J. Hepatol. 2007, 47, 83–92.
  27. Kersten, S.; Seydoux, J.; Peters, J.M.; Gonzalez, F.J.; Desvergne, B.; Wahli, W. Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting. J. Clin. Investig. 1999, 103, 1489–1498.
  28. Leone, T.C.; Weinheimer, C.J.; Kelly, D.P. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA 1999, 96, 7473–7478.
  29. Shimano, H.; Sato, R. SREBP-regulated lipid metabolism: Convergent physiology—Divergent pathophysiology. Nat. Rev. Endocrinol. 2017, 13, 710.
  30. Guo, D.; Hlavin Bell, E.; Mischel, P.; Chakravarti, A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr. Pharm. Des. 2014, 20, 2619–2626.
  31. Beuers, U.; Hohenester, S.; de Buy Wenniger, L.J.M.; Kremer, A.E.; Jansen, P.L.; Elferink, R.P.O. The biliary HCO3− umbrella: A unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010, 52, 1489–1496.
  32. Cai, S.-Y.; Boyer, J.L. Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. Inflamm. Cell Signal. 2017, 4, e1561.
  33. McGlone, E.R.; Bloom, S.R. Bile acids and the metabolic syndrome. Ann. Clin. Biochem. 2019, 56, 326–337.
  34. Gorden, D.L.; Myers, D.S.; Ivanova, P.T.; Fahy, E.; Maurya, M.R.; Gupta, S.; Min, J.; Spann, N.J.; McDonald, J.G.; Kelly, S.L. Biomarkers of NAFLD progression: A lipidomics approach to an epidemic1 . J. Lipid Res. 2015, 56, 722–736.
  35. Perakakis, N.; Polyzos, S.A.; Yazdani, A.; Sala-Vila, A.; Kountouras, J.; Anastasilakis, A.D.; Mantzoros, C.S. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism 2019, 101, 154005.
  36. Mayo, R.; Crespo, J.; Martínez-Arranz, I.; Banales, J.M.; Arias, M.; Mincholé, I.; Aller de la Fuente, R.; Jimenez-Agüero, R.; Alonso, C.; de Luis, D.A. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol. Commun. 2018, 2, 807–820.
  37. Gorden, D.L.; Ivanova, P.T.; Myers, D.S.; McIntyre, J.O.; VanSaun, M.N.; Wright, J.K.; Matrisian, L.M.; Brown, H.A. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS ONE 2011, 6, e22775.
  38. Puri, P.; Baillie, R.A.; Wiest, M.M.; Mirshahi, F.; Choudhury, J.; Cheung, O.; Sargeant, C.; Contos, M.J.; Sanyal, A.J. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46, 1081–1090.
  39. Loomba, R.; Quehenberger, O.; Armando, A.; Dennis, E.A. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis1. J. Lipid Res. 2015, 56, 185–192.
  40. Chiappini, F.; Coilly, A.; Kadar, H.; Gual, P.; Tran, A.; Desterke, C.; Samuel, D.; Duclos-Vallée, J.-C.; Touboul, D.; Bertrand-Michel, J. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients. Sci. Rep. 2017, 7, 46658.
  41. Ščupáková, K.; Soons, Z.; Ertaylan, G.; Pierzchalski, K.A.; Eijkel, G.B.; Ellis, S.R.; Greve, J.W.; Driessen, A.; Verheij, J.; De Kok, T.M. Spatial systems lipidomics reveals nonalcoholic fatty liver disease heterogeneity. Anal. Chem. 2018, 90, 5130–5138.
  42. Jung, Y.; Lee, M.K.; Puri, P.; Koo, B.K.; Joo, S.K.; Jang, S.Y.; Lee, D.H.; Jung, Y.J.; Kim, B.G.; Lee, K.L. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2020, 52, 1603–1614.
  43. Luukkonen, P.K.; Zhou, Y.; Sädevirta, S.; Leivonen, M.; Arola, J.; Orešič, M.; Hyötyläinen, T.; Yki-Järvinen, H. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1167–1175.
  44. Luukkonen, P.K.; Tukiainen, T.; Juuti, A.; Sammalkorpi, H.; Haridas, P.N.; Niemelä, O.; Arola, J.; Orho-Melander, M.; Hakkarainen, A.; Kovanen, P.T. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight 2020, 5, e132158.
  45. Mazi, T.A.; Borkowski, K.; Newman, J.W.; Fiehn, O.; Bowlus, C.L.; Sarkar, S.; Matsukuma, K.; Ali, M.R.; Kieffer, D.A.; Wan, Y.-J.Y.; et al. Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. Free Radic. Biol. Med. 2021, 172, 490–502.
  46. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357.
  47. Ooi, G.J.; Meikle, P.J.; Huynh, K.; Earnest, A.; Roberts, S.K.; Kemp, W.; Parker, B.L.; Brown, W.; Burton, P.; Watt, M.J. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J. Hepatol. 2021, 75, 524–535.
  48. Perez-Diaz-del-Campo, N.; Riezu-Boj, J.I.; Marin-Alejandre, B.A.; Monreal, J.I.; Elorz, M.; Herrero, J.I.; Benito-Boillos, A.; Milagro, F.I.; Tur, J.A.; Abete, I.; et al. Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. Diagnostics 2021, 11, 1083.
  49. Ogawa, Y.; Kobayashi, T.; Honda, Y.; Kessoku, T.; Tomeno, W.; Imajo, K.; Nakahara, T.; Oeda, S.; Nagaoki, Y.; Amano, Y. Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study. Hepatol. Res. 2020, 50, 955–965.
  50. Wang, Z.-H.; Zheng, K.I.; Wang, X.-D.; Qiao, J.; Li, Y.-Y.; Zhang, L.; Zheng, M.-H.; Wu, J. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Hepatobiliary Pancreat. Dis. Int. 2021, 20, 452–459.
  51. Jambulingam, N.; Forlano, R.; Preston, B.; Mullish, B.H.; Portone, G.; Baheer, Y.; Yee, M.; Goldin, R.D.; Thursz, M.R.; Manousou, P. Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2023, 24, 3563.
  52. The Scarred Liver Project: A New Diagnostic Pathway to Detect Chronic Liver Disease across Primary and Secondary Care, NICE (n.d.). Available online: https://www.nice.org.uk/sharedlearning/the-scarred-liver-project (accessed on 25 October 2022).
  53. Abeles, R.D.; Mullish, B.H.; Forlano, R.; Kimhofer, T.; Adler, M.; Tzallas, A.; Giannakeas, N.; Yee, M.; Mayet, J.; Goldin, R.D. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Aliment. Pharmacol. Ther. 2019, 49, 1077–1085.
  54. Lovric, A.; Granér, M.; Bjornson, E.; Arif, M.; Benfeitas, R.; Nyman, K.; Ståhlman, M.; Pentikäinen, M.O.; Lundbom, J.; Hakkarainen, A. Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. Sci. Rep. 2018, 8, 14200.
  55. Preuss, C.; Jelenik, T.; Bódis, K.; Müssig, K.; Burkart, V.; Szendroedi, J.; Roden, M.; Markgraf, D.F. A New Targeted Lipidomics Approach Reveals Lipid Droplets in Liver, Muscle and Heart as a Repository for Diacylglycerol and Ceramide Species in Non-Alcoholic Fatty Liver. Cells 2019, 8, 277.
  56. Okada, L.S.d.R.R.; Oliveira, C.P.; Stefano, J.T.; Nogueira, M.A.; da Silva, I.D.C.G.; Cordeiro, F.B.; Alves, V.A.F.; Torrinhas, R.S.; Carrilho, F.J.; Puri, P.; et al. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH—Proteomic and lipidomic insight. Clin. Nutr. 2018, 37, 1474–1484.
  57. Cantero, I.; Abete, I.; del Bas, J.M.; Caimari, A.; Arola, L.; Zulet, M.A.; Martinez, J.A. Changes in lysophospholipids and liver status after weight loss: The RESMENA study. Nutr. Metab. 2018, 15, 51.
More
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , , , , ,
View Times: 221
Revisions: 2 times (View History)
Update Date: 26 Apr 2023
1000/1000